Transparent, promt
and comprehensive
- information straight to the point

News

08/31/10, Research & Development Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 more

08/04/10, Bayer HealthCare Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot Line Session at ESC 2010 more

08/04/10, Diagnostic imaging FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging more

In Focus

Image: Tibet 08/13/2010
Bayer Schering Pharma supports special training for doctors in Tibet It’s hard to visit a doctor in rural Tibet. With better local health care, there’s less need for costly trips to distant medical centres: 40 Doctors from across Tibet are preparing to go back to their rugged rural clinics armed with new skills and techniqu... more